verified SJR 2,063 · Q1 • database Scopus / SJR & Web of Science indexed

Netherlands · Elsevier B.V.

workspace_premium Q1 — Pharmacology lock Subscription

Neurotherapeutics

Neurotherapeutics is a journal indexed in SJR in Pharmacology and Neurology (clinical) with an H index of 143. It has a price of 3690 €. It has an SJR impact factor of 2,063 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,063.

Neurotherapeutics focuses its scope in these topics and keywords: autism, invasion, experience, neuronal, research, macrophages, immunomodulatory, monocytederived, micefluidbased, cocaineexposed, ...

ISSN: 1933-7213

Publisher: Elsevier B.V.

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

2,063 Q1

H-index 143

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.690 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

2,063

H-index

143

Docs (year)

145

Docs 3y

469

Total refs

11640

Cites 3y

3032

Citable 3y

442

Cites/Doc 2y

6.85

Ref/Doc

80.28

Immediate OA

3690 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cell Therapy for Multiple Sclerosis

Use of sensory methods for detecting target engagement in clinical trials of new analgesics

Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology

Commentary: The prospect of cell-based therapy for epilepsy

Commentary: Physical approaches for the treatment of epilepsy: Electrical and magnetic stimulation and cooling

Commentary: Novel delivery approaches for antiepileptic drugs: Hope and hurdles

Commentary: Hormones, diet, and botanicals

Commentary: A skeptical view of experimental gene therapy to block epileptogenesis

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

CGRP receptor antagonism and migraine

Cell-Based Therapy for Neural Disorders - Anticipating Challenges

SHOW MORE ARTICLES

Cell Therapy for Spinal Cord Injury by Neural Stem/Progenitor Cells Derived from iPS/ES Cells

A Systems Approach to Drug Discovery in Alzheimer's Disease

Calpain as a therapeutic target in traumatic brain injury

Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease

Beneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain Injury

Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Assessment of Motor Units in Neuromuscular Disease

Approaching a new age in Duchenne muscular dystrophy treatment

Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies

ALS drug development: Reflections from the past and a way forward

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity

FAQs

Neurotherapeutics has an SJR of 2,063 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3690 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Neurotherapeutics is 23%.

Neurotherapeutics

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Neurotherapeutics?

What is the APC / publication cost?

What is the acceptance rate?